HCQ CLINICAL TRIALS

HCQ CLINICAL TRIALS WILL RESUME

World Health Organisation said that clinical trials of the drug hydroxychloroquine will resume

Hydroxychloroquine – which has anti – inflammatory and antiviral properties

It inhibited the coronavirus in laboratory experiments, but has not been proven effective in humans, particularly in placebo-controlled, randomised clinical trials considered the gold standard for data.

.

Hydroxychloroquine (HCQ): It is a medication used to prevent and treat malaria

Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda

Hydroxychloroquine is in the antimalarial and 4-aminoquinoline families of medication.

The drug label advises that hydroxychloroquine should not be prescribed to individuals with known hypersensitivity to 4-aminoquinoline compounds

Other contraindications, and caution is required if the person considered for treatment has certain heart conditions, diabetes, or psoriasis

Side effects may include vomiting, headache, changes in vision, and muscle weakness, allergic reactions, vision problems, and heart problems.

Hydroxychloroquine and chloroquine are extremely toxic in overdose.

Hydroxychloroquine has similar pharmacokinetics to chloroquine, with rapid gastrointestinal absorption, large distribution volume, and elimination by the kidneys

Hydroxychloroquine increases lysosomal pH in antigen-presenting cells.

In inflammatory conditions, it blocks toll-like receptors on plasmacytoid dendritic cells (PDCs).